AXCAN SCANDIPHARM
PharmaAXCAN SCANDIPHARM is a pharmaceutical company focused on Oncology.
AXCAN SCANDIPHARM's Key Drugs
AXCAN SCANDIPHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AXCAN SCANDIPHARM's Recent FDA Approvals
New NDA/BLA approvals for AXCAN SCANDIPHARM over the last two years — novel drugs only, excluding generics and label supplements.
AXCAN SCANDIPHARM's Therapeutic Areas
AXCAN SCANDIPHARM's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AXCAN SCANDIPHARM's Top Competitors
AXCAN SCANDIPHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AXCAN SCANDIPHARM Pipeline Snapshot
Active clinical trials for AXCAN SCANDIPHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2003-08-01
- Latest
- 2020-01-01
- Applications
- 1